Abstract
Bacterial efflux pumps are essential components of multidrug resistance, capable of expelling a wide variety of antibiotics. While specificity is traditionally attributed to static binding affinities, this study proposes that the thermodynamic forces driving these pumps—the proton motive force (PMF)—actively tune their selectivity. Using Markov jump process models, we demonstrate that periplasmic pH and membrane potential independently shift the "sweet spot" of optimal drug binding affinity. This suggests that bacteria can dynamically adjust their resistance profiles by modulating their internal and external environments, offering a new perspective on non-equilibrium biological machines.
The Efflux Pump Paradox
Multidrug resistance remains a primary challenge in global health, with bacterial efflux pumps serving as a first line of defense. These molecular machines, such as the AcrAB-TolC system in E. coli, reside in the bacterial membrane and physically transport antibiotics out of the cell.
The central paradox of these pumps is their "broad specificity": they recognize an immense variety of drug molecules while avoiding the accidental expulsion of essential nutrients. Traditionally, this selectivity was thought to be determined solely by the equilibrium binding affinity ($K_D$) of the pump's binding pocket. However, this paper investigates whether the proton gradient and electric potential—collectively the proton motive force (PMF)—play a more active role in defining transport specificity.
Kinetic Modeling of Pump Operation
To explore this, the authors developed two mathematical models based on Markov jump processes, treating the pump as a discrete cyclic stochastic machine.
- Three-state kinetic model: A minimal unicyclic model tracking transitions between empty, drug-bound, and proton-bound states.
- Five-state kinetic model: A more detailed representation that separates conformational changes, drug release, and proton release into distinct steps.
These models utilize local detailed balance relations to ensure thermodynamic consistency while operating far from equilibrium. By parameterizing these models with data from the AcrAB-TolC and MexAB-OprM systems, the researchers calculated steady-state drug throughput under varying environmental conditions.
Key Insights: The PMF as a Tuner
The study reveals that the PMF is not merely a source of "fuel" but a sophisticated "tuner" for pump performance.
Specificity as a Non-Equilibrium Property
In equilibrium systems, binding affinity is the sole determinant of selectivity. However, because efflux pumps operate far from equilibrium, the "effective" affinity ($K_M$) becomes a dynamic variable influenced by the rate of proton flux. The coupling to the proton gradient allows these pumps to achieve higher specificity than passive channels by effectively "filtering" molecules based on their kinetic properties.
pH-Dependent "Sweet Spot" Shifts
The researchers identified an optimal binding affinity where efflux is maximized. If a drug binds too weakly, it detaches before transport; if it binds too strongly, the pump cannot release it. Crucially, changing the periplasmic pH shifts this "sweet spot." A lower pH (higher proton concentration) accelerates the pumping cycle, allowing the pump to efficiently handle drugs with lower binding affinities. In both the 3-state and 5-state models, the optimal $K_D$ shifted by a factor of approximately five as pH moved from 7 to 5.
Conclusion and Future Directions
This research highlights a fundamental trade-off between the speed of drug extrusion and the energy dissipation required to maintain the PMF. While the current models assume a strict unicyclic stoichiometry, they provide a robust framework for understanding how environmental factors influence antibiotic resistance.
The next critical step is experimental validation. By precisely manipulating periplasmic pH and membrane potential in vivo, researchers can test these predicted shifts in efflux rates. Understanding these tuning mechanisms could lead to the development of adjuvants that disrupt a pump's ability to adapt its specificity, restoring the efficacy of existing antibiotics.
Summary updated